Despite some evidence that multiple resistant subclones can arise following treatment of NSCLC patients with EGFR-targeted therapies10, 11, 23, 24, the fraction of patients that develop multiple resistance mechanisms has not been systematically evaluated. Here, EGFR is linked to non-small cell lung carcinoma.